Podcasts about Matterhorn

Len Testa and Jim Hill continue No Negative November with a look at Zootopia's new 4D adventure, listener trip-planning wisdom, and the surprising book that inspired Disneyland's first mountain. NEWS Zootopia: Better Zoo-gether debuts at Animal Kingdom — The Tree of Life theater gets a major refresh with a new story, water gags, and a charming Benjamin Clawhauser animatronic. Holiday highlights return — Tree of Life Awakenings now plays nightly thanks to early sunsets, and the beloved Merry Menagerie puppet experience returns November 14. Storytime with Santa Deadpool — A holiday twist hits Avengers Campus, complete with meta Christmas jokes and Greek Orthodox canon accuracy. Listener questions answered — From the best Bay Lake Tower villas for New Year's Eve fireworks to whether it's time for Tables in Wonderland to return. Disney's shrinking parades — Why the Festival of Fantasy looks lighter on dancers and floats—and how Disney's still managing two parades a day at Magic Kingdom. FEATURE The Making of the Matterhorn — Jim shares the wild story of how a 1950s family film led Walt Disney to send a postcard from Switzerland that simply said: “Build this.” How Banner in the Sky and Third Man on the Mountain inspired Walt's alpine obsession. Why the Matterhorn nearly became a luge-style attraction (yes, really). The creative legacy of director Ken Annakin, whose films also led to Swiss Family Treehouse and Sleeping Beauty Castle. Full show notes available here: Show Notes HostsJim Hill — X/Twitter: @JimHillMedia | Instagram: @JimHillMedia | Website: jimhillmedia.comLen Testa — BlueSky: @lentesta.bsky.social | Instagram: @len.testa | Website: touringplans.com Support the Show Love what we do? Support The Disney Dish on Patreon for exclusive bonus shows and early access: patreon.com/jimhillmedia Follow Us Facebook: @JimHillMediaNews | YouTube: @jimhillmedia | TikTok: @jimhillmedia Produced by Edited by Dave Grey Produced by Eric Hersey — Strong Minded Agency Sponsor This episode is brought to you by Unlocked Magic, powered by DVC Rental Store. Save up to 10% on Disney park and event tickets, including Mickey's Very Merry Christmas Party and Jollywood Nights — only at unlockedmagic.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Len Testa and Jim Hill continue No Negative November with a look at Zootopia's new 4D adventure, listener trip-planning wisdom, and the surprising book that inspired Disneyland's first mountain. NEWS Zootopia: Better Zoo-gether debuts at Animal Kingdom — The Tree of Life theater gets a major refresh with a new story, water gags, and a charming Benjamin Clawhauser animatronic. Holiday highlights return — Tree of Life Awakenings now plays nightly thanks to early sunsets, and the beloved Merry Menagerie puppet experience returns November 14. Storytime with Santa Deadpool — A holiday twist hits Avengers Campus, complete with meta Christmas jokes and Greek Orthodox canon accuracy. Listener questions answered — From the best Bay Lake Tower villas for New Year's Eve fireworks to whether it's time for Tables in Wonderland to return. Disney's shrinking parades — Why the Festival of Fantasy looks lighter on dancers and floats—and how Disney's still managing two parades a day at Magic Kingdom. FEATURE The Making of the Matterhorn — Jim shares the wild story of how a 1950s family film led Walt Disney to send a postcard from Switzerland that simply said: “Build this.” How Banner in the Sky and Third Man on the Mountain inspired Walt's alpine obsession. Why the Matterhorn nearly became a luge-style attraction (yes, really). The creative legacy of director Ken Annakin, whose films also led to Swiss Family Treehouse and Sleeping Beauty Castle. Full show notes available here: Show Notes HostsJim Hill — X/Twitter: @JimHillMedia | Instagram: @JimHillMedia | Website: jimhillmedia.comLen Testa — BlueSky: @lentesta.bsky.social | Instagram: @len.testa | Website: touringplans.com Support the Show Love what we do? Support The Disney Dish on Patreon for exclusive bonus shows and early access: patreon.com/jimhillmedia Follow Us Facebook: @JimHillMediaNews | YouTube: @jimhillmedia | TikTok: @jimhillmedia Produced by Edited by Dave Grey Produced by Eric Hersey — Strong Minded Agency Sponsor This episode is brought to you by Unlocked Magic, powered by DVC Rental Store. Save up to 10% on Disney park and event tickets, including Mickey's Very Merry Christmas Party and Jollywood Nights — only at unlockedmagic.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Mousedebaters talk Sounds of DisneylandThis week on Mousedebaters, we're putting our mouse ears to the test—literally. Join Luke, Brittany, and Kami as we try to identify real sounds from videos of our Disneyland trip. Is that the Matterhorn's yeti roar or just Luke's stomach before churros? Hard to say.Then we wrap up spooky season with a perfectly deranged game of “Disney Halloween Musical Casting.” From Young Frankenstein to Little Shop of Horrors, we recast your favorite creepy musicals with Disney and Muppet characters. Think Fozzie as Igor, Ursula as Audrey II, maybe Goofy as... Frankenstein's monster?! I don't know, you'll just have to listen to find out.As always, we're not your kids' Disney podcast. PG-13 chaos for grown-up ears only.

In this episode of the Oncology Brothers podcast, we dived into the key takeaways from ESMO 2025, focusing on gastrointestinal (GI) malignancies. Join us as we welcomed Dr. Rachna Shroff, a GI medical oncologist from the University of Arizona, to discuss the latest studies and their implications for clinical practice. Episode Highlighted: •⁠  ⁠ctDNA in Colorectal Cancer: DYNAMIC-III and PEGASUS studies, examining the evolving role of ctDNA as a prognostic and potential predictive tool in early-stage colon cancer. •⁠  ⁠STELLAR-303: Learn about the promising results of immunotherapy in refractory MSI-stable colorectal cancer and the associated toxicities. •⁠  ⁠MATTERHORN: Updated data on durvalumab with FLOT in the perioperative setting is changing the standard of care for upper GI malignancies. •⁠  ⁠FORTITUDE-101 Study: FGFR2b target in metastatic gastric and GE junction adenocarcinoma. Tune in for an insightful discussion that highlights the latest advancements in oncology and their potential impact on patient care.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to check out our previous episodes for more insights on conference highlights, recent approvals, and treatment algorithms. #ESMO2025 #GIOcology #ctDNA #ColorectalCancer #Immunotherapy #OncologyBrothers #PrecisionMedicine

Send us a textA ruby-red cocktail, a carousel in view, and a debate we've wanted to settle for ages: which Fantasyland truly delivers the magic? We put Disneyland and Magic Kingdom head-to-head on the four things that matter most to park fans—food, layout, rides, and shows—and the results aren't as simple as coast pride.We start with the Handsome Brute and a quick reality check on price, then dive into dining. Florida brings the firepower with Cinderella's Royal Table, Be Our Guest, Gaston's Tavern, and a spread of quick-service spots, while Anaheim counters with the fan-favorite Red Rose Tavern and that coveted Grey Stuff. From value to character dining, we map where each land feeds your day best.Then we shift to what you feel the second you step through the castle. Disneyland's Fantasyland is a storybook square—tight, kinetic, and overflowing with classics like Mr. Toad, Alice, Pinocchio, and the canal boats, anchored by the Matterhorn. Magic Kingdom stretches wider, with Seven Dwarfs Mine Train at its core and Storybook Circus on the edge; it's generous in space and rich in queues, but less cohesive in spirit. On shows and characters, Florida wins with Mickey's PhilharMagic, Enchanted Tales with Belle, Princess Fairytale Hall, and reliable meet-and-greets. On rides, California's stacked lineup and intimate flow make a powerful case for the original.We wrap with practical strategy: rope drop plans, when to chase Peter Pan, how better queues can redeem longer waits, and why layout shapes the mood of your entire day. If you love the deep comfort of Disney nostalgia or crave a day packed with dining and character moments, you'll know exactly where to go next.If this helped you choose your next park day, follow the show, share it with a Disney-loving friend, and leave a quick review to tell us which Fantasyland gets your vote.

Following a fruitful European Society of Medical Oncology (ESMO) Congress 2025 for gastrointestinal malignancies, CancerNetwork® organized an X Spaces discussion hosted by 3 experts. They were Nicholas J. Hornstein, MD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health; Timothy Brown, MD, an assistant professor in the Department of Internal Medicine and the associate program director of the Hematology & Oncology Fellowship at UT Southwestern Medical Center; and Udhayvir S. Grewal, MD, an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Each doctor focused on a specific disease type, highlighting the most important abstracts in colorectal cancer, pancreatic neuroendocrine tumors (NETs), and upper gastrointestinal cancers. The Phase 3 MATTERHORN Trial (NCT04592913) Results from MATTERHORN demonstrated that adding durvalumab (Imfinzi) to 5-fluorouracil, leucovorin (folinic acid), oxaliplatin, and docetaxel (FLOT) improved overall survival (OS) compared with FLOT plus placebo in patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, regardless of pathological status.1 In the intention-to-treat population, the median OS was not reached in either arm, and the hazard ratio (HR) was 0.78 (95% CI, 0.63-0.96; P = .021). Notably, the improvement was observed regardless of PD-L1 status; in patients with PD-L1–positive disease, the HR was 0.79 (95% CI, 0.63-0.99), and in patients with PD-L1–negative disease, the HR was 0.79 (95% CI, 0.41-1.50). “This, I believe, will seal durvalumab plus FLOT as the standard of care for resectable [gastric/GEJ] cancers,” said Brown. The Observational ASPEN Study (NCT03084770) The ASPEN study showed that active surveillance was a safe approach for patients with low-grade, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors (NETs) fewer than 2 centimeters in size.2 Of the 1000 patients enrolled in the trial, 20 patients died, of whom 18 underwent active surveillance and 2 underwent surgery. Nineteen of the deaths were unrelated to pancreatic NETs; 1 death in the surgery arm was related to a pancreatic NET. After surgery, 5 patients had disease relapse or progression. With a median follow-up of 42 months (IQR, 25-60), the OS analysis showed a P value of 0.530.  “This really settles the debate on whether or not to surgically operate on patients with a [pancreatic NET] size of [fewer] than 2 centimeters and shows that active surveillance is a safe option for these patients with pancreatic NETs [fewer] than 2 centimeters in size and non-functional NETs,” said Grewal.  Data From the Phase 2/3 FOxTROT (NCT00647530) and Phase 2 NICHE-2 (NCT03026140) Trials Neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) achieved a clinically meaningful and statistically significant improvement in long-term outcomes, including responses and survival, compared with chemotherapy strategies in patients with mismatch repair deficient (dMMR) or microsatellite instability–high (MSI-H) locally advanced colon cancer.3 In NICHE-2, neoadjuvant nivolumab plus ipilimumab achieved a 3-year disease-free survival (DFS) rate of 100% compared with 80% (95% CI, 73%-85%) with all chemotherapy strategies in FOxTROT (P

Please Follow us on: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠ ⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook ⁠⁠⁠⁠⁠! In this episode, Kimberly and Tommaso apologize for the delay in their latest release. They then dive into a discussion about their favorite meals in Italy, looking back at 28 years of travel. Key Points: Kimberly and Tommaso offer a sincere apology for the delayed episode. They recap their previous discussion on favorite cities and regions. The main topic is their favorite meals in Italy, spanning 28 years of travel experiences. Episode Highlight: First Italian Meals in Cervinia Kimberly and Tommaso recount a ski trip from Zermatt, Switzerland, down to Cervinia, Italy. Kimberly describes their incredible hunger after the challenging ski descent. Tommaso recalls his memorable Zuppa Valdostana, a rich beef broth soup with bread and fontina cheese. Kimberly shares her delight in eating polenta with fontina cheese and red wine. They reminisce about a Raclette lunch with Matterhorn views, marking it as a beautiful outdoor dining experience. Meals in Lago di Como and Florence: Kimberly shares a story about visiting friends in Lago di Como, coinciding with their annual Brunello bottling celebration. Tommaso describes enjoying five to seven-year-old Brunello with grilled beef prepared by an international meat dealer. Kimberly celebrates her 40th birthday lunch at Alvalu in Tremezzo, featuring simple tomato pasta, cured meats, and a beautiful fruit tart. They both recall the unique grappa infused with blueberries, made by monks. Rome and Florence Culinary Experiences: Tommaso shares his first carbonara experience in Rome in 2021, describing it as a moment of pure paradise. Tommaso notes the relaxed dining pace in Italy, contrasting it with the faster pace in America. Kimberly describes a simple, attractive enoteca in Rome where they enjoyed another carbonara and a mozzarella di bufala appetizer. Tommaso discusses his anticipation and enjoyment of Bisteca Fiorentina in Florence, splitting it with a friend. Kimberly remembers the bright and loud atmosphere of the Florentine restaurant, a contrast to their preferred dining setting. Southern Italy and Pizza Delights: Kimberly highlights her favorite meals in Puglia, particularly a salad with tuna, mozzarella, and local vegetables, drizzled with Puglian olive oil and served with local bread. Tommaso praises the simplicity and quality of Puglian bread. Tommaso declares his favorite pizza was in Ischia, preferring a heartier style with onions, mushrooms, and prosciutto. Kimberly recounts a standout Napolitano pizza experience in Torino, found in a residential neighborhood across the river. Tommaso reflects on the ongoing challenge of finding the “next best something” in Italian cuisine. Coffee and Truffles in Torino: Kimberly raves about the bicherine, a coffee layered with dark chocolate, espresso, and frothy cream, at Cafe Bicherine in Torino. Tommaso praises a wide noodle pasta with shaved white truffles, enjoyed during truffle season in Torino, paired with a bottle of Barolo. Join Kimberly and Tommaso as they revisit their most cherished Italian meals, sharing anecdotes and insights from decades of culinary adventures. Kimberly and Tommaso share their most memorable meals from 28 years of Italian travels, from ski trips to Roman trattorias. This episode explores Italy's diverse culinary landscape and the joy of savoring food and culture.

We talk lost Disney lore, a new giveaway, getting wet on the Matterhorn and more!  

The Matterhorn Fit All-Path Series is here including the Western, Ontario, and Quebec. Coach Eric will be leading the charge with the All-Path Ontario event with NCAA Division 1 and OHL programs set to join!Visit matterhornfitevents.com to REQUEST REGISTRATION!Wondering where we've been? Big announcement coming soon!

Zum ersten Mal konnte die Gemeinde Moutier, die noch bis Ende Jahr zum Kanton Bern gehört, Parlament und Regierung im Kanton Jura wählen. Die Wahlbeteiligung ist aber tiefer als in allen anderen Bezirken. Dafür gibt es Gründe. Weitere Themen: · Menschen demonstrieren: Nun brauche es Massnahmen gegen die Wölfe, fordern Organisationen aus den Berggebieten. Mit ihrem Frust und ihren Forderungen sind sie vors Regierungsgebäude in Bellinzona gezogen. · Norweger filmt Solo-Bergsteigung: Magnus Midtbø hat allein das Matterhorn bestiegen. Sein Film wird auf YouTube millionenfach geschaut. Die Zermatter Bergrettung befürchtet einen Nachahm-Effekt. In der Westschweiz wird damit eine Diskussion weitergeführt, die bereits seit längerem läuft – werden solche Gebirgstouren zu bedenkenlos gemacht? · Oliven fühlen sich im Tessin wohl: Im Tessin werden nicht nur «Maroni» geerntet, sondern auch Oliven. Das Klima ist für sie ideal. Für die Tessiner Landwirtschaft sind sie jedoch kaum von Bedeutung. Zu Gast: Patricia Michaud, freie Journalistin in Bern, und Iwan Santoro, Tessin-Korrespondent von Radio SRF.

Send us a textJim Clash covers extreme adventure and classic rock. Over three decades of writing for Forbes, Clash, who holds an MBA from Columbia University, has penned four books, most recently Amazon bestseller “Amplified,” about ‘60s music. His first-person stories include supersonic flights in eight separate aircraft pulling up to 9 Gs and flying to 84,000 ft; driving a Bugatti at 253 mph and Indy cars at 200 mph; expeditions to the North and South Poles; summiting the Matterhorn and 23,000-ft. Aconcagua; a C-130 flight through Category V Hurricane Dorian; chasing tornadoes; riding jet skis on 60-ft waves in Portugal; a U-2 flight to the edge of space; bullfighting; being shot point-blank in a ballistics jacket, and more. Interviews include Neil Armstrong, Mario Andretti, John Glenn, Edmund Hillary, Roger Bannister, Grace Slick, Joe Frazier, Chuck Yeager and Edward Teller. For fun, Jim gives 170-mph rides at Daytona speedway. He's a former director at The Explorers Club.See more of Jim's work at Forbes and on his FaceBook pageGet Jim's books here on AmazonSupport this Podcast:  buy me a coffeeHosted by Michael J. ReinhartMichaelJReinhart.com   Whiskey and a Map:  Stories of Adventure and Exploration.  #space #JamesClash #biggestwaves #supersonicflight

Alpenstrom 2 Frigor im Salat. Als erstes starten wir in den Text und in die neue Alpensendung mit etwas Feedback von Marci Loisach und ja auf den ersten Entwurf des Flyers für Alpenstrom 1. Da wurde im Cover ein K1 Bild verwendet und ja wie ich das eben in der Vergangenheit viel zu viel…….. Sorry ! Der Marci hat ja so was von RECHT und nun ja da separiert sich der Weizen vom Speutz oder so? Die Einstellung zum Werk und ja wie eben auch SUE schreibt - Fleiss und Consisstency - Ihr SONG - Run erscheint übrigens am 30.10 und sicher auch hier auf Radio Supersaxo. Juflu - bäsmu - cheru - nei nid und nie umcheru. Entscheiduuu u derhiner stah. Herbst - Herbst - ja wie tönt der Herbst. Hat der Herbst das Zeug dazu für Alpenstrom 2. Sind wir den der M���hlancholie nicht längst verfallen? Ist das Alphorn herbsttauglich? Diese und ganz andere Fragen stelle ich mir nicht nur selbst, sondern auch Marci Loisach, freut Euch in der neusten Alpensendung auf sein und viel diverses Feedback. Der Vorhang und der Herbst - Wir stehen im Strom - strömendes Bächlein - ja der Strom - der Fluss strömt leiser - der Wasserfall tropft als ob er an Prostata leidet, doch das ist der Herbst. Vermehrt hört man wieder Laubbläser - leise sind die Alphornbläser. Aber eben es geht ans Eingemachte und an die Vorhänge welche nun schon vor dem viel zu frühen eindunkeln, gezogen werden. Wie ein gezogener Theatervorhang - die Vorstellung ist vorbei. Die Fenster sind geschlossen und hat nicht jedes Fenster - ähnlich wie eine Münze immer auch zwei Seiten. Wir drinnen sind die Schaufensterpuppen - tragen stolz einen Walliser Schwarznasuschafwoll-Rollchragu Bikini und werden belächelt von der Welt da draussen? Ich bin nie gescheitert - ich habe 10.000 Wege entdeckt, die nicht funktioniert haben. Thomas Alva Edison. Zurück am Herd - ja es geht ans Eingemachte. Einmachgläser. Konfigläser. Frisch gereinigte Brillengläser. Laut sind nun die Laubläser, viel zu leise nun die Alphornbläser. Manch Eingemachtes und Angemachtes - das Angelachte und das Angstemache, ja das Konservierte hält wohl länger als und ja zerbrechlich ist er geworden, der Hafen der Ehe. Hochzeitstage - Gedenktage - LEBENSTAGE - Geburtstage - Herbsttage. Goldene Tage. Lärchengold und Gletscherweiss. ja äs hät nu Frigor im Salat.Blumen im Fenster. Blumen im Fenster. Ich bin Kopf - du bist Salat - sei einfach die Tat. Lehres Blatt - lehres Blatt. Selbstinszenierung wird zur Pflicht… - neue Schicht - Angst vor Gicht . Dein Lachen im Gesicht. Sorgfalt in der Anstalt. Das knallt. Die Türe die laut zu knallt. Es knallt. Knallalarm. Arm ohne Alarm - Arm ohne Alarm. Mama Mia - Pizzeria - Tschickeria - Polizia - a ha - ha ha ha - bla bla bla bläht die Blähung. M����hhhlankolie was häts dä ? M����hhhlankolie Akribisch arrangiert - Dinge tun und sie dann verwerfen - sei Unruhestifter und Mutmacher zu gleich. Zuhören statt Durchziehen. gescheitert an zu viel Freiheit. Troubadur- der Hans in allen Gassen - er konnte es nicht lassen. er war nie zu fassen. ein reisender - ein zweifelnder - tapetenwechsel - winterreifen die greifen. inventar - geht klar. der Schlüssel um es zu erreichen - vertrauen - beharrlichkeit - geduld - warten auf den Tumult . heute bin ich kult. diese zeilen sorgfältig platziert - alle guru parolen deplatziert und mich neu arrangiert- liebes-permanenz. gepflegte Tendelei.Ei Ei.Ei alle tatsachen auslachen - sei beglückend - dinge tun um sie danach zu verwerfen. zweifeln und ja gescheitert an zu viel Freiheit - die anständige Geilheit. AlpenAblenkungsmanöver - Gnade - Frivol - Alkohol - Gnade - Courage - Neuanfang !!!!!!! Mama Mia Pizzeria - Mama mia - Pizzeria ! Tschickeria - Polizia - a ha - bla bla bla - Blähung ! ich welti liebär nu as bitzi mit dier karisieru. nu gnädig a dinum Gnagi gnaguuu u hochachtungsvoll und gehorsam an dinä fittlabluttu Puttipongini liwuuu. abär dü schicks mi schaffuuu - lafru - lifru - recycluuuu - liebär nu eis laffuuu - u nie frässuu - nur nu GUTES gniessuu. muess all das archivieruuu - go stappluuu - als isch äs verbärchuuu - sie muess i dra erbrächuuu - du chef nu a tisch reservieruuu. liebesplänkelei. tendelei. ei ei ei. kei ziit nu asmal z heiratuu, nie meh ratuuu, nix meh beratuu. als isch zum üslachuu …. u welti nu as bitziiii schlafuuu - welti nu as bitziiii schlafuuu- va dier träumuuu. nie meh privatisieruuu u liebär nu as bitzi mit dier karisieru. beischläfer - siebenschläfer - mitschläfer - schlafloser schläfer - walliser Schwarznasuschaf Schäfer . ich vermittle heiterkeit in deine einsamkeit - heiterkeit in deine einsamkeit ! nie gleichgültigkeit! Äs chlisus Depressiönli hockt schich näbu mich u offeriert mär nu as Glas Cornalin. Ich lehne dankbar ab und wir bestellen eine Flasche. Morgen - ja Morgen fangen wir von vorne an - A Tropfuuu Fendärboerg mim Björn Borg. Bi der Fernanda uf ihrusch Veranda. Fleiss und Consisstency - fleiss und consisstency !!! Am Einmachen und irgendwie hat das was von Konservatorium ? Konserven und man setzt sich neben die Reserven. Was soll ich hittu poschtu - posten - Post It- Häsch gseh ? Äs hät scho sit Monat nix meh geposchtut meint z Reini - u da druf meint z wundrig Saasi - obs ächt nu läbt ? U der WaBo meint - im WB isch nix xsi. Verzettelungsagentur - Solliii - solliii - solli nid.? Selti dä scho u mag äbu grad nid. Ja äu d Fräu Muselti die welti mit dum Mr. Numunidmottu go ga u go sooo u gpschirsch där Herbst ? Frühlingsgefühle sind ja so was für Anfänger. Wer es im Herbst weiss zu tun - der ist ( isst ) kein dummes Huhn. Ergattere den letzten Mangold in einem diesen Shopping-Palästen - nie in der Stadt - nein wohl eher in der Aglomeration ? Da wo das Urbane sich beheimatet und ja früher da ernährte das Land unser Land und ja auch die Stadt. Heute trifft sich das Land und die Stadt in der Aglomeration deren eben urbanen Heimat sich so mit Ihren Parkplätzen und unser Land zu betonierte ? Ja wer leistet sich unser Land? Alles schon besprochen. Foodwaste ? Ausland so günstig fein . Wir die Schweiz so teuer und klein - lass alle und alles hinein. Wir die Schweiz so teuer und klein - in dir bin so klein. Im Lastwagen dessen Container gerade via Alpensegler zu uns geschifft wurde, befinden sich wiederum 30% Dinge die niemand kauft ? War das unser Thema ? Nein - Strom - Engergie - positive Vibes - Fotografie - amazing Beats ! Gute und goldige Herbstlaune. Und ja es ging um Mangold. Rehpfeffer. Penne. Frischkäse. Marroni. Vinotainment = Lafnetscha vam Marc Seewer Brigerbad - und ja der war zum Apéro top - ging beim Gericht etwas unter- die Frage : evlt besser etwas ROTES ? Der Pinot Noir Alexandra vom MAC CINA by DECANLI Salsgesch mit der perfekten Säure und der Balance von Eichenfass ergänzte alles perfekt. Regional. Saisonal. Romulus. Cumulus. Orgasmus. Taste for your Sex buds. Horny Chef - where have you been all my life ? Best Passion Pairing. Still bonkers about good Taste. Be horny - blow the Horn - don't climb the Matterhorn. By Walliser-Schwarznasu-Schaf-Woll Roll Chragu Bikini Poet. By the Way - Einmachgläser. Konfigläser. Leichenzerhackteilmaschine. Messer und Schneiderbretter. Pinot u Fendäbörg. Das Buch - ja mein Buch - Erzählkunst u Eigenart ( noch 6 übrig !! ) Alles im Herbst Sale - nicht im Simplon Center aber ja äbu - support the LOCALS u merci fär alls. We deliver FREE - u viellicht chochiii där z Nacht u läsu der nu a Gschichgiii üs minum Büch vor ? Danke an ALLE für ihr Feedback, an Deyrush u Novi Maschilton u Enrico Lentzin aber eine riesen Dank an Marci Loisach und sein Feedback das gab mir so viel gute Energie - ich war unter sehr gutem Strom - hab danach noch gleich Geschrieben, den Abwasch erledigt, Gedanken zu Beats und noch den Boden gekehrt - langer Abendspaziergang mit den Hunden, noch mehr Notizen, noch mehr Wein. Danke an Euch alle und ja Gedenktage - Vater unser der du bist im Himmel - ein lieben Gruss an Eliane Burki welche leider viel zu früh von uns gegangen wurde ? Hirntumor mit 39. ! Music - Marci Loisach www.marcelengeler.com #deyrush #novi_mashilton Enrico Lenzin. Eliane Burki. Gebrüder Supersaxo. Vinotainment - www.decanali.ch und www.weingutseewer.ch

Im Juli 1895 steht Albert Mummery, einer der besten Bergsteiger seiner Zeit, vor der höchsten Wand der Welt. 4.500 Meter ragt die Rupal-Wand vor ihm in die Höhe. Es ist der erste ernsthafte Versuch, einen Achttausender zu besteigen. Die Expedition endet tödlich, wie viele weitere Besteigungsversuche am Nanga Parbat im Himalaya. Wir sprechen in der Folge darüber, wie der Nanga Parbat zum Schicksalsberg der Deutschen wurde und wie es Hermann Buhl 1953 erstmals auf den Gipfel schaffte. //Erwähnte Folgen - GAG360: Unglück am Matterhorn – https://gadg.fm/360 - GAG453: Pemmikan und der Pelzhandel in Nordamerika – https://gadg.fm/453 - GAG269: Monika Ertl und ein Mord im Generalkonsulat – https://gadg.fm/269 //Literatur - Ralf-Peter Märtin: Nanga Parbat. Wahrheit und Wahn des Alpinismus, 2002. - Kriemild Buhl: Mein Vater Hermann Buhl: Der Ausnahmebergsteiger, 2024. - Podcast „Messner – ein extremes Leben“: https://www.ardaudiothek.de/sendung/messner-ein-extremes-leben/urn:ard:show:32b583b0e97d83b1/ //Aus unserer Werbung Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte: https://linktr.ee/GeschichtenausderGeschichte // Wir sind jetzt auch bei CampfireFM! Wer direkt in Folgen kommentieren will, Zusatzmaterial und Blicke hinter die Kulissen sehen will: einfach die App installieren und unserer Community beitreten: https://www.joincampfire.fm/podcasts/22 //Wir haben auch ein Buch geschrieben: Wer es erwerben will, es ist überall im Handel, aber auch direkt über den Verlag zu erwerben: https://www.piper.de/buecher/geschichten-aus-der-geschichte-isbn-978-3-492-06363-0 Wer Becher, T-Shirts oder Hoodies erwerben will: Die gibt's unter https://geschichte.shop Wer unsere Folgen lieber ohne Werbung anhören will, kann das über eine kleine Unterstützung auf Steady oder ein Abo des GeschichteFM-Plus Kanals auf Apple Podcasts tun. Wir freuen uns, wenn ihr den Podcast bei Apple Podcasts oder wo auch immer dies möglich ist rezensiert oder bewertet. Wir freuen uns auch immer, wenn ihr euren Freundinnen und Freunden, Kolleginnen und Kollegen oder sogar Nachbarinnen und Nachbarn von uns erzählt! Du möchtest Werbung in diesem Podcast schalten? Dann erfahre hier mehr über die Werbemöglichkeiten bei Seven.One Audio: https://www.seven.one/portfolio/sevenone-audio

Dirk Arnold und Harald Müller-Huesmann ordnen neue Daten ein: ctDNA-gesteuerte Therapiestrategien, adjuvante und perioperative Immunkonzepte (u. a. ATOMIC, MATTERHORN) sowie Fortschritte bei RAS-gerichteten Therapien im Pankreaskarzinom.

En esta cápsula de ESMO 2025 EXPRESS, el Dr. Juan Manuel O'Connor, oncólogo médico, jefe de la sección de Tumores Gastrointestinales del Instituto Alexander Fleming en Buenos Aires, Argentina nos comenta brevemente sobre los avances más relevantes sobre tumores gastrointestinales.El experto comenta lo siguiente: Ya se presentaron los datos del estudio MATTERHORN con resultados maduros. Como recordatorio, este estudio marca un nuevo paradigma terapéutico al incorporar la inmunoterapia junto con el esquema FLOT en el entorno perioperatorio del cáncer gástrico o de la unión gastroesofágica. Esto significa que el tratamiento logra aumentar las tasas de curación en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica localmente avanzado.Según el reporte, se observa una reducción cercana al 25% en el riesgo de muerte, y la mediana de supervivencia aún no se ha alcanzado con el seguimiento disponible. Por lo tanto, como mencionaba, este resultado representa un hallazgo relevante que confirma y fortalece los datos presentados previamente en la sesión plenaria de ASCO de este año.De cara al futuro, sería importante considerar análisis por subgrupos, especialmente en pacientes con tumores de tipo difuso o en posibles diferencias relacionadas con el género, dado que se observaron resultados algo inferiores en mujeres. Estos aspectos podrían ser criterios relevantes de estratificación en futuros estudios.En cualquier caso, se trata de un estudio positivo con hallazgos significativos. En esa misma sesión se presentó también el SKYSCRAPER-07, que se enfoca en tumores de tipo escamoso, lo que nos lleva a reflexionar y plantear nuevas preguntas sobre este campo. La pregunta es si existe alguna estrategia adicional para los pacientes que han recibido tratamiento definitivo, y en este contexto se evaluó la combinación de atezolizumab con tiragolumab, un anticuerpo anti-TIGIT, como posible alternativa terapéutica, aunque el estudio no alcanzó su objetivo principal predefinido, sí evidenció ciertas señales de actividad que sugieren un potencial beneficio de la inmunoterapia como tratamiento de consolidación en pacientes con enfermedad irresecable.Y finalmente, en el área de los tumores esofagogástricos, para comentar que me llamó la atención, en el advenimiento estos anticuerpos biespecíficos, un nuevo agente que se presentó justamente en combinación o comparando con el esquema de quimioterapia para pacientes con cáncer gástrico, HER2 positivo.Y para cerrar, en el campo de los tumores esofagogástricos, me pareció interesante destacar el avance de los anticuerpos biespecíficos, con la presentación de un nuevo agente evaluado en comparación con la quimioterapia estándar en pacientes con cáncer gástrico HER2 positivo.Entre otros temas.Fecha de grabación: 19 de octubre de 2025Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud. Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso. Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados. ESMO® es una marca registrada de la European Society For Medical Oncology. Este material ha sido producido de manera independiente y no está autorizado, patrocinado ni avalado por dicha organización.

Jen and Frank chat with Troy and Mimi from Disney Assembled Podcast about their recent trip to Disneyland. On this episode…

Eine neue Studie zur PFAS-Belastung in hochalpinen Gebieten hat überraschend hohe Werte der sogenannten Ewigkeitschemikalien festgestellt. Die höchsten Werte wurden auf dem Matterhorn und im Skigebiet Arosa gemessen. Das findet Basilius Thalmann bedenklich. Er ist Experte für Umweltchemie an der ZHAW. Raffael Sigron spricht mit ihm über die neuesten Forschungsergebnisse. Bild: ROTAUF

Gaza-Rückkehrer stehen vor dem Nichts, Schweizer Bäcker: Ärger über günstiges Aldi-Brot, Tunesien: Hölle für Migrantinnen und Migranten, YouTuber klettert alleine aufs Matterhorn

In today's episode, leading experts across oncology specialties previewed the key studies and data they are most anticipating ahead of the 2025 ESMO Congress. Dana M. Chase, MD, a professor of Clinical Obstetrics and Gynecology in the Division of Gynecologic Oncology at UCLA, discussed her excitement to see findings from a phase 1 trial (NCT05403554) investigating NI-1801 in patients with heavily pretreated, mesothelin-expressing platinum-resistant epithelial ovarian cancer. Premal H. Thaker, MD, MS, the David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology and director of Gynecologic Oncology Clinical Research at Siteman Cancer Center in Saint Louis, Missouri, discussed the anticipation for findings from a multi-omic analysis of the phase 3 AtTEnd/ENGOT-EN7 trial (NCT03603184) of atezolizumab in patients with endometrial cancer and data demonstrating that the WES-derived Aneuploidy Score may identify patients with mismatch repair–deficient endometrial cancer who derive reduced benefit from immunotherapy. Zev Wainberg, MD, the Estelle, Abe, and Marjorie Sanders Chair in Cancer Research at UCLA, shared his anticipation for new data in gastrointestinal oncology, particularly the overall survival results from the phase 3 MATTERHORN trial (NCT04592913) of durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel in patients with resectable gastric and gastroesophageal cancer, which are expected to provide pivotal updates following previously reported event-free survival outcomes. Sagus Sampath, MD, an associate clinical professor and medical director of the Department of Radiation Oncology at City of Hope in Duarte, California, highlighted the phase 2 NorthStar trial (NCT03410043) evaluating osimertinib (Tagrisso) with or without local consolidative therapy in patients with metastatic EGFR-mutated non–small cell lung cancer (NSCLC).

Diese Woche war in Appenzell wieder «Gässschau» – die Ziegenschau. Die kleinen, weissen, zottligen Appenzeller Ziegen gelten als gefährdet. Der Bestand hat im letzten Jahrhundert abgenommen oder stagniert. Die weiteren Themen: (00:03:04) Im Dörrhaus Im ganzen Land gab es früher in den Gemeinden Dörrhäuser. In Erlinsbach gibt es das immer noch. Im Herbst geht die Dorfbevölkerung zum Häuschen und lässt ihr Pilze und Früchte in den über 100 Jahre alten Öfen dörren. (00:05:40) Von der Bankerin zur Winzerin Sie hatte eine führende Position in einer Bank. Dann schmiss sie alles hin – und startete eine Lehre als Winzerin: Heute ist die Luzernerin Nicole Theiler die Weinbau-Fachperson der Zentralschweizer Kantone. (00:08:52) Die Wandbilder im Bahnhof Basel In der Schalterhalle empfangen sechs grosse Gemälde mit Matterhorn, Jungfraujoch und Vierwaldstättersee die Reisenden. Sie wurden vor rund 100 Jahre aufgehängt, um für touristische Ziele zu werden. Zugluft und Dreck setzen den Bildern zu. Sie werden deshalb restauriert. (00:11:45) 25 Jahre nach der Katastrophe von Gondo Bei Überschwemmungen und Murgängen kamen im Walliser Bergdorf 13 Menschen ums Leben. Das Dorf wurde wieder aufgebaut, aber viele sind weggezogen, die Schule ist geschlossen. Welche Parallelen gibt es zu Blatten?

Tim Fritz hat sich einen Traum erfüllt und ist vom Gipfel des Matterhorns mit dem Gleitschirm geflogen. +++ Das Matterhorn kann man wohl zurecht als Ikone der Berge der Alpen bezeichnen. Seine pyramidenförmige Spitze ist weltbekannt. Wenn man die steilen Felsflanken vor Augen hat, würde man nicht unbedingt auf die Idee kommen, dort mit dem Gleitschirm starten zu wollen. Aber es gibt Menschen, die genau davon träumen. Und es gibt solche, die diesen Traum sogar realisieren. Darf ich vorstellen: Tim Fritz. Der 37-jährige aus Todtnau im Schwarzwald ist Anfang September 2025 erst solo in einem Zug auf das Matterhorn geklettert. Dort hat er sich dann von einem kleinen Schneefeld knapp unter dem Gipfel mit seinem Single-Skin-Schirm in die Lüfte geschwungen. Viele Stunden Aufstieg standen am Ende zehn Minuten Abflug gegenüber. In dieser Folge 171 von Podz-Glidz erzählt Tim Fritz von diesem und weiteren Abenteuern rund ums Hike and Fly, Climb and Fly, Bike and Fly und Ski and Fly. Zum Beispiel einer Reise vom tiefsten zum höchsten Punkt Europas, bei der er es schaffte, letztendlich kein einziges Mal in die Luft zu kommen. +++ Wenn Du Podz-Glidz und den Blog Lu-Glidz fördern möchtest, so findest Du alle zugehörigen Infos unter: https://lu-glidz.blogspot.com/p/fordern.html +++ Musik dieser Folge: Track: By Myself | Künstler: The Grey Room Youtube Audio Library https://www.youtube.com/watch?v=iaQ73X5cxsY +++ Lu-Glidz Links: + Blog: https://lu-glidz.blogspot.com + Facebook: https://www.facebook.com/luglidz + Instagram: https://www.instagram.com/luglidz/ + Whatsapp-Kanal: https://whatsapp.com/channel/0029VaBVs05CHDynzdlJlU34 + Youtube: https://youtube.com/@Lu-Glidz + Soundcloud: https://soundcloud.com/lu-glidz + Spotify: https://open.spotify.com/show/6ZNvk83xxGHHtfgFjiAHyJ + Apple-Podcast: https://itunes.apple.com/de/podcast/podz-glidz-der-lu-glidz-podcast/id1447518310?mt=2 + Linktree: https://linktr.ee/luglidz +++ LINKS zu Tim Fritz + Tim Fritz‘ Bergschule Bergwärts: https://xn--bergwrts-4za.com/ + Tim Fritz auf Instagram: https://www.instagram.com/_timfritz_/ + Video vom Abflug am Matterhorn: https://www.instagram.com/_timfritz_/reel/DOWOzZciC8u/

Ein vom Bund in Auftrag gegebenes ETH-Gutachten bringt den Ausbau der Autobahn im Grauholz trotz Volksnein wieder auf den Tisch. Der Bypass Bern Ost hingegen hält Professor Ulrich Weidmann nicht für prioritär, ganz zum Missfallen der Stadt Bern. Weiter in der Sendung: · Ein norwegischer Sportkletterer hat ein Video gedreht, das ihn ungesichert und alleine auf seinem Weg auf das Matterhorn zeigt. Das Video wurde bereits millionenfach geklickt. Was birgt das für Gefahren? Experten geben Auskunft. · Das Freiburger Kantonsparlament macht bei der Diskussion über die Sparmassnahmen Eingeständnisse. Dabei profitieren jene, die beim Kanton am wenigsten verdienen.

Send us a textGet ready to ROCK with Sam, Kevin, and Amanda as we honor the legacy of Fred Joerger—the rockwork artist and model builder who helped shape the very foundation of Disneyland. From miniature models of Sleeping Beauty Castle to the towering peaks of the Matterhorn and Big Thunder Mountain, Fred's work turned blueprints and concept art into believable masterpieces. We explore his career before, during, and after his time as an Imagineer, and how his fingerprints continue to tell stories at the parks today. Then, in our Imagineering Armchair segment, we dream up new ways to bring naturalistic detail and miniature magic back into the parks—just as Fred would have done. We invite you to become Armchair Imagineers with us! Please share your thoughts and join the conversation about this episode and more on our Discord!Don't miss her stories, laughs, and the Disney magic that keeps us all coming back for more!Join us in our completely free Discord https://discord.gg/4nAvKTgcRnCheck out all of our amazing sponsors!Getaway Todayhttps://www.getawaytoday.com/?referrerid=8636If you want to book a Disney Vacation, please use our friends at Getaway Today. Also, if you call 855-GET-AWAY and mention Walt's Apartment, you will get a special dose of magic Where In The Park The Podcast-“Discover the history behind the details of Disney parks and more on the Where In The Park podcast”https://whereinthepark.comCheck Out Sunken City Designs - from the mind of Louis Medinahttps://sunkencitydesigns.bigcartel.comWe are proud to be part of the Disney Podcast Family , checkout all the other great shows below https://linktr.ee/DisneyPodcastFamily

The Matterhorn, Nestlé Chocolate, and a long-standing history of neutrality, Switzerland has it all. However, the Swiss were too busy enjoying all those comforts and fell asleep at the wheel for the past few decades...Join the Patreon here: https://www.patreon.com/PeterZeihanFull Newsletter: https://mailchi.mp/zeihan/the-swiss-are-screwed

Anne Lindboe er Oslos ordfører, men visste du at hun er en verdensvant klatrer, som har besteget både Matterhorn og Mont Blanc? Einar får henne i studio for å lære mer om dette, hvordan det er å dra rundt i verden og bestige gigantiske steinrøyser, hvilke topper hun har i kikkerten og en debreif av en eksotisk tur til den undervurderte ferieperlen Slovenia.Er du keen på å høre om de respektive landene som fjellene befinner seg i? Skaff deg et Podimoabonnement og hør landepisodene på podimo.no/198land, da vel!Produsert av Martin Oftedal, PLAN-B Hosted on Acast. See acast.com/privacy for more information.

This episode of the The Coffee Club, Daily Show Podcast, starts with a discussion about upcoming sporting events, from the Winter Olympics in Milan and Cortina, Italy, to the Summer Olympics in Los Angeles. Janae and Ronnie also touch on some terrifying and sad topics, including a hoax about Carson Wentz's father's death and a discussion about scams that prey on people's emotions. They then shift gears to a more uplifting topic: the upcoming Veterans Honor Flight. Later, the hosts share some "Did You Know" facts, discuss what they love about fall, and debate whether listening to audiobooks counts as reading. The conversation also covers some "terrifying" but normal aspects of daily life, like driving, aging, and childbirth, and the hosts share some wild news stories about a bear attack in Yellowstone and a youth baseball practice struck by stray bullets. The highlight of the episode is an interview with Patrick Kirby of Do Good Better Consulting on Nonprofit Day. Patrick shares insights on the current state of nonprofit giving, emphasizing the shift towards large donors and the importance of showing donors the impact of their contributions. The show wraps up with more news, including the latest from NASA and an update on the Matterhorn ride at Disneyland. Standout Moments: Winter Olympics are Next Year: The hosts realize the Winter Olympics are happening in Milan and Cortina, Italy, in February 2026. (00:00:27) A Hoax About Carson Wentz's Father: A discussion about a social media hoax claiming the death of Carson Wentz's father. (00:02:40) Veterans Honor Flight: Details are shared about the upcoming Veterans Honor Flight on Tuesday, the 30th, asking the community to welcome the 204 veterans home at the Fargodome. (00:05:32) North Dakota Reading Proficiency: A concerning statistic is revealed: the average reading proficiency rate for students in North Dakota is only 44%. (00:08:18) The Terrors of Everyday Life: The hosts talk about everyday activities that are "terrifying," including driving, having children, and ride-sharing. (00:20:46) The State of Nonprofits: Guest Patrick Kirby explains how nonprofit donations have changed since COVID, with fewer individual donors but larger contributions from major donors. (00:23:45) The Importance of Gratitude: Patrick Kirby stresses the importance of nonprofits showing gratitude and demonstrating the impact of donations. (00:26:00) Reindeer are Real: The hosts share a surprising "Did You Know" moment about reindeer being real animals. (00:35:54) Disneyland's Submarine Voyage: The history of the original Disneyland submarine…

You might think Marie is a travel planner. You might think she is a health care professional. Stick around, because once you hear it, you might just change your mind about . . . EPIC MARIE. Yep. Epic Marie is here to dish about her experiences at Universal and also tell us how wrong we are about all of our previous episodes. In this episode, you will be able to: Discover what makes Epic Universe a game-changer in Orlando's theme park scene and why it might just become your new favorite spot. Compare Universal's Epic Universe and Disneyland to uncover which park offers the best experiences for your next epic adventure. Identify the must-try rides at Epic Universe that deliver unforgettable thrills and unique storytelling you won't find anywhere else. Explore the secrets of the Wizarding World of Harry Potter Ministry of Magic and why it's a must-see for any Potter fan visiting Epic Universe. Uncover the top dining options at Epic Universe that combine great flavors with immersive atmospheres to fuel your park day perfectly. The key moments in this episode are:00:00:01 - Introduction and Single Riders Dating App Humor 00:06:00 - Spokes and Hub Crawl Podcast Structure Explained 00:16:17 - Planning and Staying Near Epic Universe Theme Park 00:18:58 - Optimal Time and Attractions to Experience at Epic Universe 00:26:40 - Layout and Ride Variety in Super Nintendo World vs. Other Lands 00:29:43 - Dark Universe Experience and Scary Atmosphere Insights  00:36:11 - Ministry of Magic Ride Review and Technical Breakdown 00:41:30 - Exploring Epic Universe's Kids' Attractions and Ride Experiences 00:43:40 - Disney and Universal Coasters 00:52:10 - Future Expansion and Theming Predictions for Epic Universe 00:55:20 - Universal's Epic Universe vs. Disney World00:58:45 - Supreme Resort Concierge Insights and Podcast Ad Break 01:00:50 - Sleeping Beauty vs. Cinderella Castle 01:03:45 - Everest, Matterhorn, Indiana Jones, and Dinosaur 01:09:42 - Opinions on Haunted Mansion Holiday and Listener Perspectives  01:13:18 - Fun Trivia and Correcting Disney Facts  ------ Hey, have you called J. R. Trimpe yet? Do you need music? Because you should really call him. https://trimpe.org Also, Marie @land_world_sea_with_marie Learn more about your ad choices. Visit megaphone.fm/adchoices

Audiotraveller Henry Barchet war für diese Episode auf den beeindruckenden Schienenstrecken des Glacier Express und des Bernina Express in den Schweizer Alpen unterwegs. Die historische Dampflok der Furka-Bahn hat ihn für ein Interview auf über 2100 Meter transportiert und bei der Fahrt mit der Gornergrat-Bahn hatte er einen unverstellten Blick auf das Matterhorn. Mehr über das faszinierende Schienennetz der Schweiz in dieser Episode. Weitere Informationen zu Bahnreisen in der Schweiz unter Lernidee Bahnreisen und Bahnurlaub . 00:00 Intro 02:06 Gornergrat-Bahn 05:30 Furka-Bahn 11:55 Glacier Express 18:35 Bernina Express 21:08 Gotthard-Linie 24:18 Reiseinformationen Diese Episode wurde in Zusammenarbeit mit Lernidee-Erlebnisreisen produziert.

Mary Poppins would say, "Just a Spoonful of Sugar Helps the Medicine go Down". Well, I've seen that happen as it's been my.privilege to work with organizations big and small, public, private and non-profit. Many of them come to me because they want their organization to be something more like Disney. They want a place where people enjoy working and even have fun at it. In truth, few organizations work harder than Disney. And at the end of the day, it's work. But despite the hard times, the difficult circumstances, and the day-to-day challenges, leaders stay positive despite the circumstances. There are Disney inspired lessons that can show us all how to keep a sense of humor, how to create a space for fun, how not to take themselves too seriously, and even how to find joy in accomplishing the impossible. From the boardroom to the Matterhorn; from Canoe Races to Goofy's Mystery Tour--join us as we learn lessons from Disney leaders past and present about how to create fun--even at work! ________________________________________________________________ Disney Insights YouTube Page--Check it out and subscribe. DisneyInsights.com--So many resources at our home site. Be sure to subscribe to receive notice of upcoming podcasts. Disney Insights Facebook Page--Come join and interact in conversation with others. My newest book, A Century of Powerful Disney Insights, Volume I 1923-1973, The Walt & Roy Disney Years is available!  Also, check out my two of my other books, The Wonderful World of Customer Service at Disney and Disney, Leadership and You.  Also, for those examining other business benchmarks beyond Disney, check out Lead with Your Customer: Transform Culture and Brand Into World-Class Excellence. ________________________________________________________ Check out Zanolla Travel to book your next vacation! David & Leah Zanolla ZanollaTravel.com Owner/Agents (309) 863-5469 ____________________________________________________________________ Performance Journeys This podcast and post is provided by J. Jeff Kober and Performance Journeys, which celebrates more than 20 years as a training and development group bringing best in business ideas through books, keynotes, workshops, seminars and online tools to help you take your organization to the next level. Want a Keynote Speaker? More than just nice stories, I offer proven insight and solutions having worked in the trench. Need Consulting? I've worked for decades across the public, private and non-profit arena.  Need Support? We offer so many classroom, online, and other resources to help you improve your customer service delivery, leadership excellence, and employee engagement. Contact us today, and let us help you on your Performance Journey!

Dreaming of panoramic views and sparkling alpine lakes on your Swiss Alps travel adventure? If alpine hiking, charming mountain villages, and unforgettable mountain excursions are on your wishlist, this episode is for you.In this episode, I'm joined by Claudia Wyss from Zermatt Cableways as we explore one of Switzerland's most scenic walks, the famous Five Lakes Hike. Starting from Blauherd and making our way to the stunning Stellisee, Claudia shares her best tips for hiking in Switzerland, from choosing the right gear to finding the best photo spots for that perfect Matterhorn reflection.You'll hear about other must-do adventures in Zermatt, including riding the Gornergrat railway, taking in the views from Matterhorn Glacier Paradise, and heading up to Rothorn for sweeping mountain panoramas. We also chat about family-friendly adventure activities like mountain carts, kickbikes, and playgrounds by alpine lakes.Claudia's insider knowledge is your must-have Switzerland travel guide, with suggestions for timing your hikes, enjoying local cuisine, and making the most of seasonal offers like sunrise tours.Whether you're looking for your first taste of alpine hiking or you've explored Switzerland before and want to discover more hidden gems, this episode will leave you inspired, informed, and ready to lace up your hiking boots.Tune in now to discover the five reasons the Five Lakes Hike should be on your Switzerland travel itinerary.Safe travels,Carolyn

Kim and her daughter Mia just got back from a mother-daughter trip to Switzerland. They celebrated her high school graduation with a grad trip and since Mia loves mountains and she was already going to be in France with a school trip, Switzerland was her top choice! They visited Geneva, Zermatt and the Jungfrau Region because they really wanted to focus on the mountains. Altogether they spent eight nights in Switzerland and they moved around a lot. The itinerary included: 1 night in Geneva 2 nights in Zermatt to see the Matterhorn 2 nights in Grindelwald 2 nights in Wengen 2 nights in Lucerne If you are going to Switzerland and you really want to spend time in the mountains, skip Geneva and Lucerne and focus more on the smaller towns, not the cities. Their favorite town was Zermatt for hiking and also wine tasting. Grindelwald was the other favorite because of the hotel and the view of Eiger. Some of the activities included: Visit the old town in the cities (e.g. Geneva) Hiking (which are harder than you might expect even on trails described as easy, use Google Maps to see elevation, buy or bring hiking poles if you can and are checking a bag) Cable cars (which are pricey) Matterhorn Glacier (you can also ski even in the summer) Alpine slides / mountain coaster / ziplines The train is a great way to get around the country and if you use a Swiss Rail Pass you also get transportation on some of the cable cars (but not all). It makes it very easy because you don't need to worry about buying tickets. First class will give you more seating options and it is less crowded so it is quieter. It is hard to use the trains if you have large luggage as some of the trains are more for locals/commuters. Try to pack light if you can or use a luggage forwarding service. It is better to stay longer in each destination as you spend a lot of time transiting up and down the mountains via train/cable car. Basing yourself in Murren or other smaller towns ends up with a lot of time waiting for transportation. It makes more sense to stay in Grindelwald, Interlaken, or Lauterbrunnen. When planning a trip, be sure to plan at least six to nine months in advance if you want to stay in town and at the better hotels. Also, when considering different hotels, the hospitality is wonderful but look closely at the amenities that are offered. Most don't have air conditioning but it wasn't needed in the mountains. Some hotels have screens on the windows but not all and there are a lot of flies and some mosquitoes. Keep in mind that shops close early (6-7 pm) and that busses also stop running by 7:00 pm in small towns. Hotels and meals are very expensive in Switzerland, especially now that the dollar is weak against the CHF and Euro. Main entrees are 30-50 CHF per person, salads 12-19 CHF, and beer was cheap but wine was expensive. To save money, you can buy wine or beer at the grocery store to enjoy before you go out. Drink sizes are also very small. The food is a lot of fondue, cheese, pasta, raclette, and chocolate. Other regions might have more regional specialties. Otherwise there are a lot of burgers and international cuisine. If you do have allergies, there are a lot of peanuts and other nuts being served as a snack or included in dishes. Credit cards can be used almost everywhere. In all the tourist areas, everyone spoke English. They were less accommodating in the city or non-tourist establishment. Be sure to pack and wear sunscreen. It is hard to find places to refill a water bottle so you may want to carry your own snacks and drinks.

✨ Ever wondered what's really behind that mysterious door in New Orleans Square? Or what goes on inside the Matterhorn when you're not on the bobsleds?In this exclusive Patreon episode, I'm taking you on a tour of the hidden side of Disneyland—the places most guests never get to see. From Club 33 and the now-legendary Dream Suite to backstage breakrooms, secret tunnels, and yes… even a basketball court tucked inside a mountain.We'll peek behind closed doors, above Main Street windows, and into the cast-only corners that keep the magic running. Whether you're a casual fan or a diehard Disneyland detective, you're going to love these stories, secrets, and little-known facts.Thank you for supporting Mix In Some Magic on Patreon—this episode is just for you.

Scott McKibben is the CEO and Co-founder of Matterhorn Venture Partners, a Chicago-based firm that specializes in acquiring, developing, and managing value-added industrial real estate across the US. With a career spanning over 30 years, Scott has overseen more than $10.6 billion in transactions and has developed and acquired more than 80 million square feet of industrial and office properties — making a significant impact on the commercial real estate industry. A former NCAA Division I tennis player at DePaul University and a graduate of the University of Wisconsin, Scott brings a competitive and disciplined approach to deal-making and team building. In this episode… Many real estate professionals face the challenge of scaling profitably while adapting to unpredictable market cycles. With rising interest rates, fierce competition, and shifting project economics, building a resilient investment firm requires more than capital — it demands vision, adaptability, and the ability to attract top-tier talent. How can today's dealmakers structure firms that weather downturns and still deliver strong returns? Scott McKibben, a seasoned commercial real estate executive, shares how he launched his firm with a lean, MVP-style approach — assembling a team of trusted colleagues and offering shared ownership to create true alignment. With over $10 billion in transactions and 80 million square feet of industrial and office projects under his belt, Scott reflects on lessons from both legacy deals and new ventures. He explains why backing local partners as 50-50 co-owners leads to entrepreneurial agility, how persistence and adaptability helped him navigate projects like the Citadel Center pivot, and why securing equity before chasing deals is a discipline he swears by. In this episode of the Inspired Insider Podcast, Dr. Jeremy Weisz interviews Scott McKibben, Co-founder and CEO of Matterhorn Venture Partners, about building high-impact real estate ventures. Scott shares his journey from leadership at Brennan Investment Group to launching MVP, strategies for recruiting top talent, and the importance of transparency and trust with investors. He also dives into the mindset that fuels long-term success, the role of relationships in sourcing deals, and how sports taught him the grit and discipline needed to thrive in real estate.

Join us as we celebrate 5 years of the podcast and talk about our reviews and other classic moments

The lads return with a tiki-fueled tales of: summer brain fog, terrifying theme park rides, and a very unexpected encounter at Vegas' Golden Tiki. They dive into the new Walt Disney animatronic at Disneyland—does it honor the man or haunt your dreams? (he has a pillow for that). Plus: a punk rock museum detour, brutal tiki bar opinions (sorry, Palm Springs), and how Jungle Cruise jokes still come in handy at Costco. If you love Disney parks, tiki culture, or just laughing at weird Vegas stories, this is the episode is for you.

Jeffrey Adolf Epstein. Isn't there a guy who owns the Smithsonian called Smith something? 1000 butts a day. I Didn't Order THCeeeeeeEEEEeeeeeeeeee! Inherently Voluptuous Rabbits. Riki Tiki Toddler. Do elephants have paws? Cause I'd like really wanted to know. Wasn't the head of the Manson Family called Charlie Something? Smoke Pizza Everyday. What's the Matterhorn? It's a bird, It's a plane! It's a squiggly line! Spy Women. Papa Ibbott Dunks on Everyone. Both Sides of the Aisle Are Covered in Cheetos Dust. None of your business with Wendi and more on this episode of The Morning Stream. Hosted on Acast. See acast.com/privacy for more information.

Jeffrey Adolf Epstein. Isn't there a guy who owns the Smithsonian called Smith something? 1000 butts a day. I Didn't Order THCeeeeeeEEEEeeeeeeeeee! Inherently Voluptuous Rabbits. Riki Tiki Toddler. Do elephants have paws? Cause I'd like really wanted to know. Wasn't the head of the Manson Family called Charlie Something? Smoke Pizza Everyday. What's the Matterhorn? It's a bird, It's a plane! It's a squiggly line! Spy Women. Papa Ibbott Dunks on Everyone. Both Sides of the Aisle Are Covered in Cheetos Dust. None of your business with Wendi and more on this episode of The Morning Stream. Hosted on Acast. See acast.com/privacy for more information.

Don't miss the latest Thinking Thoracic episode as host Erin Gillaspie, MD, is joined by Stephanie Worrell, MD, associate professor, University of Arizona, and thoracic surgeon, Banner Health, for a lively and insightful post-ASCO discussion. Together, they unpack the significance of the CheckMate 577 and Matterhorn trials, and explore what these groundbreaking studies mean for the future of esophageal and gastroesophageal junction cancer care.

And when I say "you" I really mean "we" and when I say "have to" I really mean might do.Join our book club!https://patreon.com/LifeonBooks?utm_medium=unknown&utm_source=join_link&utm_campaign=creatorshare_creator&utm_content=copyLinkJoin the Life on Books mailing list to stay up to date on all of our latest book giveaways, projects, and more!https://linktw.in/BRYAnVhBooks mentioned in this episode (purchasing through these links helps support the show!)Carpenteria by Alexis Wrighthttps://amzn.to/3J1j2Fihttps://bookshop.org/a/103053/9780811...The USA Trilogy by John Dos Passoshttps://amzn.to/3H3SKlchttps://bookshop.org/a/103053/9780063...The War at the End of the World by Mario Vargas Llosahttps://amzn.to/40DG5Mthttps://bookshop.org/a/103053/9780312...Endurance by Alfred Lansinghttps://amzn.to/4o7qY8chttps://bookshop.org/a/103053/9780465...Something Happened by Joseph Hellerhttps://amzn.to/46nfgzShttps://bookshop.org/a/103053/9780684...Passing by Nella Larsenhttps://amzn.to/3J0JvCShttps://bookshop.org/a/103053/9780142...Hunchback by Sauo Ichikawahttps://amzn.to/44LSlwXhttps://bookshop.org/a/103053/9780593...Matterhorn by Karl Marlanteshttps://amzn.to/45inOXIhttps://bookshop.org/a/103053/9780802...A Book of Memories by Péter Nádashttps://amzn.to/4m5KFLIhttps://bookshop.org/a/103053/9780312...The Public Burning by Robert Cooverhttps://amzn.to/418IvCZhttps://bookshop.org/a/103053/9780802...The Ice-Shirt by William T. Vollmannhttps://bookshop.org/a/103053/9780140...https://amzn.to/4546Jj3Dog Soldiers by Robert Stonehttps://amzn.to/3H3otmzhttps://bookshop.org/a/103053/9780395...Stoner by John Williamshttps://amzn.to/3GZLZkuhttps://bookshop.org/a/103053/9781590...Middle C by William Gasshttps://amzn.to/41end6Xhttps://bookshop.org/a/103053/9780804...Gesell Dome by Guillermo Saccomannohttps://amzn.to/40xgAMThttps://bookshop.org/a/103053/9781940...The Combinations by Louis Armandhttps://amzn.to/3H3TPcKhttps://bookshop.org/a/103053/9781739...The Crying of Lot 49 by Thomas Pynchonhttps://bookshop.org/a/103053/9780060...https://amzn.to/4oaV0IkGravity's Rainbow by Thomas Pynchonhttps://amzn.to/4o1QT1bhttps://bookshop.org/a/103053/9780143...Empty Wigs by Jonathan Meadeshttps://amzn.to/4f3svIchttps://bookshop.org/a/103053/9781800...A Naked Singularity by Sergio De La Pavahttps://amzn.to/4kWUFpFhttps://bookshop.org/a/103053/9780226...On Being Blue by William Gasshttps://amzn.to/450yg4QA Posthumous Confession by Marcellas Emantshttps://amzn.to/4l1qE8iMoby Dick by Herman Melvillehttps://amzn.to/3J4afCshttps://bookshop.org/a/103053/9780142...Shadow Ticket by Thomas Pynchonhttps://amzn.to/3J1A3z7https://bookshop.org/a/103053/9781594...Their Eyes Were Watching God by Zora Neale Hurstonhttps://amzn.to/4l0r52Lhttps://bookshop.org/a/103053/9780060...Invisible Man by Ralph Ellisonhttps://amzn.to/4m68mnahttps://bookshop.org/a/103053/9780679...Bamarzo by Manuel Mujica Lainezhttps://bookshop.org/a/103053/9781681...Miaow by Benito Perez Galdoshttps://amzn.to/40zbVtPSchattenfroh by Michael Lentzhttps://amzn.to/40xgYuPhttps://bookshop.org/a/103053/9781646...Sorrow of War by Bao Ninhhttps://amzn.to/40BlNmZhttps://bookshop.org/a/103053/9780525...The Quiet American by Graham Greenehttps://amzn.to/4mhl2b3https://bookshop.org/a/103053/9780143...An Oral History of Atlantis by Ed Parkhttps://amzn.to/46Y6cl8https://bookshop.org/a/103053/9780812...Vulture Capitalism by Grace Blakeleyhttps://amzn.to/4fgfdIEhttps://bookshop.org/a/103053/9781982...Europe Central by William T. Vollmanhttps://amzn.to/46WBxoohttps://bookshop.org/a/103053/9780143...The Boulevard by Jared Edsonhttps://amzn.to/4kXsHu4Anniversaries by Uwe Johnsonhttps://amzn.to/416ASgmAhab Sequels by Pierre Sengeshttps://amzn.to/4kYxOu2https://bookshop.org/a/103053/9781940...

Tell us about your Adventure!Life is a journey filled with exploration, and few experiences rival the joy of discovering nature with family. Recently, Craig had the pleasure of embarking on an unforgettable adventure with his daughters. Their trips were brimming with breathtaking views and exhilarating activities—ranging from skiing in the stunning Swiss Alps to hiking into the depths of the Grand Canyon. This journey was not just an adventure; it was a celebration of nature's beauty and the thrill of bonding with loved ones.

Alex brings the history for The Matterhorn, a Disneyland California classic. Mags and Ryan try to stay on course, but things sometimes go off the tubular steel track. .For more Dizneyverse, head over to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dizneyverse.com⁠⁠ or check us out on Instagram @Dizneyverse ⁠https://www.instagram.com/dizneyverse/one⁠Check out our Tee-Public page for a shirt or sticker. ⁠http://tee.pub/lic/tEDcAPdSVFA⁠

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to bring a discussion of key data from the phase 3 MATTERHORN trial (NCT04592913), which were presented at the 2025 ASCO Annual Meeting. MATTERHORN was a randomized, double-blind, multinational study evaluating the addition of durvalumab (Imfinzi) to FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) in patients with previously untreated, resectable gastric or gastroesophageal junction adenocarcinoma. In the MATTERHORN trial, 948 patients were randomly assigned 1:1 to receive either durvalumab or placebo in combination with perioperative FLOT, followed by 10 cycles of durvalumab or placebo as adjuvant therapy. The primary end point was event-free survival (EFS); secondary end points included overall survival (OS) and pathological complete response (pCR). The trial met its primary end point. Durvalumab plus FLOT (n = 474) significantly improved EFS vs placebo plus FLOT (n = 474; HR, 0.71; 95% CI, 0.58-0.86; P < .001), representing a 29% reduction in risk of progression, recurrence, or death. The interim OS analysis showed a nonsignificant trend favoring durvalumab (HR, 0.78; 95% CI, 0.62-0.97; P = .025). The pCR rate was 19% (95% CI, 15.75%-23.04%) with durvalumab vs 7.2% (95% CI, 5.02%-9.88%) with placebo. Toxicity profiles were comparable between the 2 groups, though immune-related adverse effects were more frequent with durvalumab. Importantly, the addition of durvalumab did not delay surgery or initiation of adjuvant therapy. Although the MATTERHORN regimen is not yet FDA approved or included in the National Comprehensive Cancer Network guidelines, this trial demonstrates a promising EFS benefit and potential practice-changing implications, pending mature OS data and further molecular subgroup analyses, according to Armstrong and Tawagi.

This week's episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025,  the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA. 

“I'll take your ‘Lord of This World' and raise you ‘After Forever'…”   From “The Moses story” to “the shortest verse in The Good Book” to one of the creepiest spoken word intros in all of metal which references end time prophecy, the impact of GOD IN METAL can be found everywhere, no matter how subtle or obvious, positive or negative.   Whether it's an album cover, a band's name, a song, or even direct Biblical scripture, there are endless references to GOD IN METAL across all genres of heavy metal, and we barely even mentioned Christian metal.   Discover the truth about “A.I.” and why “pretty clean is not clean enough” (for some), learn about the “Christmas Vacation” reference (and the ensuing drama) we forgot to mention on our recent Metallica concert review, be sure to always exercise prudence & discernment regarding the concept of “easy hole” and remember that “Yeah, That Dude is huge, too” when you JOIN US for The Bunkerpoon Revival as we behold the divinely everlasting and eternally omnipotent impact of GOD IN METAL.   Visit www.metalnerdery.com/podcast for more on this episode Help Support Metal Nerdery https://www.patreon.com/metalnerderypodcast Leave us a Voicemail to be played on a future episode: 980-666-8182   Metal Nerdery Tees and Hoodies – metalnerdery.com/merch Follow us on the Socials: Facebook - Instagram - TikTok Email: metalnerdery@gmail.com Can't be LOUD Enough Playlist on Spotify Metal Nerdery Munchies on YouTube @metalnerderypodcast   Show Notes: (00:01): “It was a teen club…” (NOT to be confused with #YoungLife) / “And the reason is YO!” / ***WARNING: #listenerdiscretionisadvised *** / “Shut up man, the music's still playing…”/ #metalnerderysong / “You know what A.I. is, right?” / “I was a safety…you were the quarterback, sir…you were feeding the ball…to the receiver…”/ #footballtalk / “Pretty clean is not enough clean…”/ “Every time a woman begs me…you know they beg for it all the time…”/ ***WELCOME BACK TO THE METAL NERDERY PODCAST IN THE BUNKERPOON DIGITAL DUNGEON!!!*** / #markallthetimes / #thisepisodesbeeroftheepisode #Scofflaw #Float #WatermelonLimeShandy / “That's a #KISS song, right?” / #TheVerdict / “Limey watermelon?” / Pears vs Apples / “It's like tumbleweeds down there…” (09:19): PATREON SHOUT OUT!!! / ***JOIN US over on the #Patreon at patreon.com/metalnerderypodcast for all kinds of stuff that you won't get anywhere else!!!*** / “It's 99.9% guaranteed…kinda like #condoms…” / #wiiings instead of #wings / “Going back to the last episode, what we forgot to mention…”/ #Bethany / “There was a couple that were extra #twanglified…”/ “You know what I didn't know…”/ #MaeQuestal #ChristmasVacation #BettyBoop / “Do you think she would have been easy hole?” / #easyhole #investmenthole / PATREON SHOUT OUT (CONTINUED) #PatreonShoutOut / “Everything's gay when you get married…” (17:44): #MatthewsReflections / #TheCharismaticVoice / “She's done some metal stuff…and she did #RainingBlood…” / “I watched a couple, and they did…I don't remember who it was, but she's got dark hair…Jinjer? It might have been #Jinjer…” / “You know what we forgot to do on the last episode?” / EMAIL US at metalnerdery@gmail.com VOICEMAIL US at 980-666-8182 & SOCIAL MEDIA US at #metalnerderypodcast on #Instagram #Facebook #YouTube #TikTok / “It was Jinjer…”/ #SlayerOfTheEpisode #MCTentacleChoice THE ANTICHRIST (Show No Mercy – 1983)  (25:25): “Reflections…let's see…”/ #RussellsReflections / #JayJayFrench #TwistedSister / ***Check out his #audiobook (and/or regular book) - Twisted Business: Lessons from My Life in Rock ‘n' Roll*** / “We've gotta do a dive on that…”/ “Here's the path: either it's a gradual build or a Matterhorn spike…”/ “He said he made more off that album than he ever did with Twisted Sister…” / #Sevendust / “I don't wanna tell the whole story…”/ “Tim Robbins? Or Tony Robbins?” / “That dude's huge, too, and he's got big fingers…”/ “There was a couple in front of us…they took a perfectly framed #selfie with them, my mug, and my #MetalNerderyShirt …” (37:37): #TheDocket #AlmightyThen METAL NERDERY PODCAST PRESENTS:  GOD IN METAL / #ChristianMetalBands / “No limits…anything that's #God #tangentional…” / #TheAlmighty / #Dio HOLY DIVER (Holy Diver – 1983) / #shinydiamonds #cleantigers / NOTE: #RockyIII came out almost a year to the day before #HolyDiver / “I have #faith that you've got it in you…” / #Metallica CREEPING DEATH (Ride The Lightning – 1984) / #BushOfFire #LandOfGoshen / (REFERENCE: Exodus 3, Exodus 12) / “It's also a redhead's downstairs…” / “You got one?” / #BlackSabbath LORD OF THIS WORLD (Master of Reality – 1971) / “I'll take your Lord of this World and raise you After Forever…” / “It's 1971, it's the fall, and I'm high…”/ “That one's more about…” / #AfterForeverLyrics / “Going back to our #MachineHead episode…” / (REFERENCE: John 11:35) (48:56): “The Dave/Metallica thing keeps making the rounds…” / #Metallica THE FOUR HORSEMEN (Kill ‘Em All – 1983) / (REFERENCE: Revelation 6) / “Actually this part is more relevant…”/ “I've got a surprise one to throw you off…” / #LedZeppelin THE BATTLE OF EVERMORE (Led Zeppelin IV – 1971) / “The Prince of Peace embraced the gloom, and walked the night alone…”/ “We are not all seeing…because we all have glasses…”/ #IronMaiden REVELATIONS (Piece of Mind – 1983) /( REFERENCE: G.K. Chesterson O God of Earth and Altar, Psalm 47:7) /  “It's like going to Wal-Marks…Krogers…” (56:48): “I mean, we talking deities or…?” / “It's got a lot of melody…”/ #TypeONegative CHRISTIAN WOMAN (Bloody Kisses – 1993) / “If you look at the first #DOWN album…” / #CyclingFrog / “Okay wait a minute, how's that different from In League with Satan!?” / #Forbidden FORBIDDEN EVIL (Forbidden Evil – 1988) / “Behold good God the Savior will rule Eternity…” / “It appears that Metallica kinda wins with #BiblicalReferences or references to #God…”/ “You'll have to hold all four of your horses…”/ #Sepultura ARISE (Arise – 1991) (1:08:04): “I'm not gonna do it, but you know what I mean…” / #Rammstein ENGEL / #Angel / “I don't know what he's saying…”/ “Their live show is nothing but fire…”/ “It's all about That Dude…” / #Slayer JESUS SAVES (Reign In Blood – 1986) / “That's all you say…”/ “I feel like religion has wronged that man somehow…” / “Here's the irony though…if you see that on an album…” / “I'm sorry Russell, you walked in at a very awkward moment…” / #SuicidalTendencies SEND ME YOUR MONEY (Lights…Camera…Revolution! – 1990) / “Now let's have some silence…for all you sinners!” / “That's probably my favorite guitar tone…of ALL thrash…” / #steakaupoivre (1:17:51): “You reached for all the Satanic shit right out of the gate…”/ “No, that's about having a baby…”/ #Creed MY OWN PRISON (My Own Prison – 1997) / “This is where #TheDocket came from…”/ “Nuts how?”/ #BlackSabbath GOD IS DEAD? (13 – 2013) / “This is SO Sabbath…this could have been 1972…”/ “Was NOT expecting that!” / #IronMaiden / (REFERENCE: Revelation 12:12 & 13:18) THE NUMBER OF THE BEAST (The Number Of The Beast – 1982) / “In the mist, what kind of figures move and twist?” / “It's like #fignewtons but…you just heard it wrong…”/ THANK YOU FOR JOINING US!!! / “Do you know who filled in for them on tour?” / #TwistedSisterTrivia #untilthenext #outroreel ***GO PURCH SOME MERCH AT metalnerdery.com/merch ***  

Dr. Shaalan Beg and Dr. Kristen Ciombor discuss practice-changing studies in GI cancers and other novel treatment approaches that were presented at the 2025 ASCO Annual Meeting. Transcript Dr. Shaalan Beg: Hello, I'm Dr. Shaalan Beg, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas, Texas. There were some remarkable advances in gastrointestinal cancers that were presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Kristen Ciombor to discuss some exciting GI data. Dr. Ciombor is the Ingram Associate Professor of Cancer Research and a co-leader of Translational Research and the Interventional Oncology Research Program at the Vanderbilt Ingram Cancer Center. Our full disclosures are available in the transcript of this episode. Dr. Ciombor, it's great to have you on the podcast today. Dr. Kristen Ciombor: Thanks, Dr Beg. It's great to be here. Dr. Shaalan Beg: Alright, let's kick it off. Big year for GI cancers. We'll start off with LBA1. This was the ATOMIC study sponsored by NCI and the National Clinical Trials Network (NCTN) and the Alliance group. This is a randomized study of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for stage III mismatch repair deficient colorectal cancer. Dr. Kristen Ciombor: I think this study was really definitely practice-changing, as you can tell because it was a Plenary. But I do have some concerns in terms of how we're actually going to implement this and whether this is the final answer in this disease subtype. So, as you said, the patients were enrolled with stage III resected mismatch repair deficient colon cancer, and then they were randomized to either modified FOLFOX6 with or without atezolizumab. And that's where it starts to become interesting because not many of us give FOLFOX for 6 months like was done in this study. Obviously, the study was done over many years, so that was part of that answer, but also the patients received atezolizumab for a total of 12 months. So the question, I think, that comes from this abstract is, is this practical and is this the final answer? I do think that this is practice-changing, and I will be talking to my patients with resected mismatch repair deficient colon cancer about FOLFOX plus atezolizumab. I think the big question is, do these patients need chemotherapy? And can we do a neoadjuvant approach instead? And that's where we don't have all the answers yet. Dr. Shaalan Beg: Yeah, but it has been great to see immunotherapy make its way into the adjuvant space after having made such a big impact in the metastatic space, but still some unanswered questions in terms of the need for chemotherapy and then the duration of therapy, which I guess we'll have to stay tuned in for the next couple of years to to get a lot of those questions answered. Dr. Kristen Ciombor: Yeah, but a big congratulations to the study team, to the NCTN, the NCI. I mean, this is really a great example of federally funded research that needs to continue. So, great job by the study team. The DFS 10% difference is really very large and certainly a practice-changing study. Dr. Shaalan Beg: Yeah, and and sticking with colon cancer, and and this another federally funded study, but this time funded by a Canadian cancer clinical trials group was LBA3510. This is the CHALLENGE study. It's a randomized phase 3 trial of the impact of a structured exercise program on disease-free survival for stage III or high-risk stage II colon cancer. This study got a lot of buzz, a lot of mainstream press coverage, and a lot of discussions on what that means for us for the patients who we're going to be seeing next week in our clinic. What was your takeaway? Dr. Kristen Ciombor: Yeah, this is a really interesting study, and I was so glad to see it presented because this partially answers one of the questions that patients always have for us in clinic, right? You know, once they've completed their standard chemotherapy and surgery, what else can they do to help prevent recurrence? And so we've always known and sort of extrapolated that healthy lifestyle habits are good, but now we have data, particularly in these patients. Most of them were stage III colon cancer patients, those had high-risk stage II cancer. And basically, the goal was to increase their physical activity by at least 10 MET hours per week. So, my big question, of course, as I came into this presentation was, “Okay, what does that mean exactly? How does that translate to real life?” And really what the author presented and explained was that basically most patients could hit their target by adding a 45- to 60-minute brisk walk 3 to 4 times a week. So I think this is very approachable.  Now, in the confines of the study, this was a structured exercise program, so it wasn't just patients doing this on their own. But I do think kind of extrapolating from that, that this is very achievable for most patients. And not only did this prevent recurrence of their prior cancer, but actually the rate of new primary cancer diagnoses, was less, which is really interesting, especially in the breast and prostate cancer. So this was a really interesting, and I think practice-changing study as well, especially given that this is something that most patients can do. Dr. Shaalan Beg: Yeah, and there was a lot of discussion in the hallways after the presentation in terms of how this really changes our existing practice because most folks already recommend exercise as a way for improving outcomes in cancer patients. So we've already been doing that. Now we have some data on how much it can impact the benefit. But there was some discussion about what the actual degree of impact was. There was a drop-off rate in terms of how long folks were able to stick with this exercise regimen. But you've seen this in clinic when someone have their surgery, they have their chemotherapy, they've been so intimately involved with the oncology world, with the oncology practice, and they somehow feel that they're being let loose into this mean, angry world without any guidance and they're looking for something to do. “What more can I do in terms of my lifestyle?” And then here we have very solid data, as solid as can be for an intervention like exercise, showing that there is an impact and you can give a prescription for exercise when someone wraps up their chemotherapy for colon cancer, thanks to the study. Dr. Kristen Ciombor: Yeah. It was a great study. Dr. Shaalan Beg: Moving to gastroesophageal cancer, another late-breaking abstract. This is LBA5. The MATTERHORN trial was a phase 3 trial of durvalumab plus FLOT for resectable GE junction and gastric cancer. And again, another area where immunotherapy has made an impact, and here we're seeing it move closer for earlier-stage disease. What was your take-home for the MATTERHORN trial? Dr. Kristen Ciombor: Yeah, so this study looked at neoadjuvant perioperative durvalumab plus our current standard chemotherapy of FLOT versus placebo plus FLOT. And this was a large study, almost 1,000 patients were randomized. And the primary endpoint was event-free survival, and it was definitely met in favor of the D + FLOT arm, as Dr. Klempner discussed after Dr Janjigian's presentation. I do think there are still some unanswered questions here. Overall survival is not yet mature, so we do have to wait and see how that shakes out. But it's very interesting and kind of is reflective of what, as you said, we're looking at earlier and earlier lines of therapy, particularly with immunotherapy, in these GI cancer spaces. So it makes a lot of sense to test this and and to look at this. So the toxicity was pretty similar to what we would expect. Primary endpoint was met, but again, we'll have to wait and see what the survival data looks like. Dr. Shaalan Beg: Yeah, and in oncology, we know, especially for treatment that does add additional cost, it does add additional potential toxicity that we want to see that overall survival nudged. I did see some polls on social media asking folks whether their practices changed from this, and I think the results were favoring adding durvalumab for this group of patients but understanding that there are caveats to the addition of treatments and the eventual FDA approval in that indication as well. Dr. Kristen Ciombor: Exactly. I completely agree with that. Dr. Shaalan Beg: All right. How about we stick with gastroesophageal cancer? LBA4002 was trastuzumab deruxtecan versus ramucirumab plus paclitaxel for second-line treatment in HER2-positive unresectable or metastatic gastric cancer or GE junction cancer. This was the DESTINY-Gastric04 study. And again, antibody-drug conjugates making a big impact across different diseases. And here we have more data in the HER2-positive gastric cancer space. Your thoughts on this study? Dr. Kristen Ciombor: Yeah, so this is a really important space in gastroesophageal cancer because the HER2 positivity rate is fairly high as compared to some of our other tumor types. So, I do think one of the important things was that patients did have biopsy confirmation of HER2 status, which was very important, and then they were randomized to either T-DXd versus the kind of second-line standard of ramucirumab-paclitaxel. So this was a great practical study and really answers a question that we had for a while in terms of does anti-HER2 therapy in the second-line really impact and improve survival. So we did see a statistically significant improvement favoring T-DXd. I do think it's always important to look at toxicity, though, too. And there was about almost 14% rate of interstitial lung disease, which of course is the most feared toxicity from some of these antibody-drug conjugates, especially T-DXd. So I do think it's important to keep that in mind, but this is definitely a great addition to the armamentarium for these HER2-positive patients. Dr. Shaalan Beg: And pancreas cancer was on the stage after a very long time with a positive clinical trial. This is Abstract 4006. These were preliminary results from a phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone for previously untreated metastatic pancreas cancer. This is a frontline clinical trial of gemcitabine/nab-paclitaxel plus/minus the study drug. There were other cohorts in this study as well, but they reported the results of their part 3B arm. And great to see some activity in the pancreas space. And your thoughts? Dr. Kristen Ciombor: Yeah, we definitely need better treatments in pancreas cancer. This was a very welcome presentation to see. The elraglusib is an inhibitor of GSK-3beta, and it's thought that that mediates drug resistance and EMT. And so this is, I think, a perfect setting to test this drug. So patients basically were randomized. Patients with metastatic pancreas cancer were randomized 2: 1 to gemcitabine/nab-paclitaxel plus or minus this elraglusib. So, what we saw was that overall survival was better with the addition of this new drug. And overall, not only the 1-year overall survival, but also median overall survival.  The thing that was interesting, though, was that we saw that the overall survival rates were 9.3 months with the combination versus 7.2 months with just gemcitabine/nab-paclitaxel. And that's a little bit lower than we've seen in other studies. So, not sure what was going on there. Was it the patients that were a bit sicker? Was it a patient selection, you know, thing? I'm not really sure how to explain that so much. Also, the toxicity profile was much higher in terms of visual impairment, with over 60% of patients being treated with the combination versus 9% with gemcitabine/nab-paclitaxel. So these were mild, grade 1 and 2, but still something to be cautious about. Dr. Shaalan Beg: And especially with this being a phase 2 trial, making sure that in a larger study we're able to better evaluate the toxicity and see if the control arm in the larger confirmatory study performs differently will be really important before this compound makes it to the clinic in our space. But very exciting to see these kinds of results for pancreas adenocarcinoma. Dr. Kristen Ciombor: Yeah. Dr. Shaalan Beg: We've talked, it seems, a couple of times on this podcast about the BREAKWATER clinical trial. We did hear PFS and updated OS data, updated overall survival data on first-line encorafenib plus cetuximab plus modified FOLFOX6 for BRAF-mutated colorectal cancer. This was LBA3500. And eagerly anticipated results – we have all previously heard the progression-free survival results – but here we heard updated overall survival results, and very well-received study it seemed from the audience that time. So what are your takeaways on the updated results for BREAKWATER? Dr. Kristen Ciombor: In my opinion, this was one of the most practice-confirming studies. As you mentioned, we've already seen some of the preliminary data of BREAKWATER at prior meetings. But really what was particularly impactful for me was the median overall survival with the BREAKWATER regimen. So, again, patients received FOLFOX, encorafenib cetuximab in the first line if they had BRAF-mutated V600E-mutated colorectal cancer. And the median PFS was 12.8 months, which was actually really remarkable in this traditionally very aggressive, poor prognosis subtype of tumors. So, by seeing a median overall survival of 30.3 months was just incredible, in my opinion. Just a few years ago, that was considered the median overall survival for all comers for metastatic colorectal cancer. And we know the median overall survival was more in the less than 12 months range for BRAF. So this was incredibly impactful, and I think should be absolutely practice-changing for anyone who is eligible for this regimen.  I think again, where the practice meets the study is what's kind of important to think about too, how long did patients get FOLFOX, and certainly it adds toxicity to add a BRAF-targeted regimen on top of FOLFOX already. So, one of the other interesting things about the study, though, was that even though it didn't complete treatment, they actually did look at encorafenib/cetuximab alone and in the first line without chemotherapy. And those preliminary results actually looked okay, especially for patients who might not be able to tolerate chemotherapy, which we certainly see in practice. So, overall, definitely more data. And I agree that it's certainly practice-changing. Dr. Shaalan Beg: And it completely, as you mentioned, changes the outlook for a person who's diagnosed with BRAF-mutated metastatic colon cancer today versus even 7 or 8 years ago. Dr. Kristen Ciombor: And we're seeing this over and over in other subtypes too, but how you choose to treat the patient up front really matters. So really giving the right regimen up front is the key here. Dr. Shaalan Beg: And along the same lines, Abstract 3501 wanted to answer the question on whether people with MSI-high metastatic colorectal cancer need double checkpoint inhibitor therapy or is single therapy enough. So this [CheckMate-8HW] study compared nivo plus ipi with nivo alone, nivo monotherapy for MSI-high metastatic colorectal cancer. And we've known that both of these are fairly active regimens, but we also know the chance of immune-related adverse events is significantly higher with combination therapy. So this was a much-needed study for this group of patients. And what were your takeaways here? Dr. Kristen Ciombor: This, of course, has been really nivo-ipi in the first-line MSI-high metastatic colorectal cancer is now a standard of care. And not everybody is eligible for it, and there could be reasons, toxicity reasons, and other things too. But as we've been seeing for the last couple of years, immunotherapy clearly beats chemo in this space. And now looking at doublet versus single immunotherapy treatment in the first line, I think really nivo-ipi does beat out monotherapy. I will say, however, there is a caveat in that we still haven't seen the nivo-ipi versus nivo in the first line. So what has been presented thus far has been across all lines of therapy, and that does muddy the waters a little bit. So definitely looking forward and and we've asked this many times and based on the statistical plan and and what not, you know, we just haven't seen that data yet. But I do think it's becoming increasingly important to consider doublet immunotherapy for these patients as long as there are no contraindications. With the again, with the caveat that we have to have these toxicity discussions in the clinic with patients because many patients can tolerate it, you know, this regimen fairly well, but there can be very severe toxicities. So, I think an informed discussion should really be had with each patient before moving forward. Dr. Shaalan Beg: Yeah, informed decision, making them aware of the potential of real significant toxicities, immune-related toxicities with double therapy. But I am curious in your practice, how often do you see people choosing doublet therapy as frontline? Dr. Kristen Ciombor: So patients are really savvy, and a lot of times they've heard this data before or have come across it in patient advocacy groups and other things, and it's really nice to be able to have that conversation of the risk versus benefit. So I will say not all of my patients choose doublet, and many of them are still cured with immunotherapy monotherapy. So the big question there is, will we ever understand who actually needs the doublet versus who can still be cured or have very good long-term outcomes with just the single agent? And that has not been answered yet. Dr. Shaalan Beg: What a great point. So the last abstract I was hoping we could talk about is POD1UM-303 or the INTERAACT2 subgroup analysis and impact of delayed retifanlimab treatment for patients with squamous cell carcinoma of the anal canal. What were your thoughts here? Dr. Kristen Ciombor: This was a study, actually we saw at ESMO, we saw the primary data at ESMO last year, and this was an update with some exploratory analyses. But this was really an important study because once again, we're looking at immunotherapy in later lines of therapy. That's how we started looking at and investigating immunotherapy, and now we're moving it up and up in the treatment course. So this was a study of carboplatin/paclitaxel plus or minus retifanlimab. Actually it was retifanlimab versus placebo. And it was a positive study, as we heard last year. This actually led to FDA approval of this regimen last month, just before ASCO, and it has now been incorporated in the NCCN guidelines as the preferred first-line option.  So what I thought was important from the additional data presented at ASCO was looking at the different subgroups, it did not appear that patients with liver mets or not had different outcomes. So that was really good to see because sometimes in colon cancer we see that immunotherapy doesn't work as well when patients have liver mets. And interestingly, because we use immunotherapy in anal cancer without any biomarkers, unlike with colon cancer or some of the other tumor types, also the authors looked at PD-L1 status, and it did look like maybe patients did a little bit better if they had higher PD-L1 expression, but patients still could benefit even if they were PD-L1 negative. So that was important, I think, and we will continue to see further data come out from this study. I want to mention also that EA2176 just completed accrual, so that was carbo-taxol plus or minus nivolumab. And so we should be seeing that data sometime soon, which will hopefully also confirm the ongoing role for immunotherapy in the first-line setting for anal cancer. Dr. Shaalan Beg: That was a fantastic review. Thank you, Dr Ciombor. Thanks for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Kristen Ciombor: Thanks for having me here. Dr. Shaalan Beg: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Shaalan Beg  @ShaalanBeg  Dr. Kristen Ciombor @KristenCiombor Follow ASCO on social media:    @ASCO on Twitter   @ASCO on BlueSky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Shaalan Beg:   Consulting or Advisory Role: Ipsen, Cancer Commons, Foundation Medicine, Science37, Nant Health, Lindus Health Speakers' Bureau: Sirtex Research Funding (Inst.): Delfi Diagnostics, Universal Diagnostics, Freenome Dr. Kristen Ciombor: Consulting or Advisory Role: Pfizer, Incyte, Exelixis, Bayer, ALX Oncology, Tempus, Agenus, Taiho Oncology, Merck, BeiGene Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calthera, Genentech, Seagen, Syndax Travel, Accommodations, Expenses: Incyte, Tempus

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Cathy Eng, a renowned GI medical oncologist from the Vanderbilt Ingram Cancer Center, to discuss the most impactful updates from the ASCO 2025 annual meeting, specifically focusing on gastrointestinal (GI) malignancies. Join us as we dive into five pivotal abstracts that are set to change the landscape of GI cancer treatment: 1.⁠ ⁠DYNAMIC III: Discover how ctDNA-guided adjuvant chemotherapy in stage 3 colon cancer did not improve outcomes, highlighting questionable role of escalating approach with ctDNA positivity. 2.⁠ ⁠ATOMIC: Learn about the addition of atezolizumab to FOLFIRI in MSI-H disease stage 3 colon cancer, which improved disease-free survival with a hazard ratio of 0.50. 3.⁠ ⁠BREAKWATER: Explore how the combination of encorafenib, cetuximab, and FOLFOX has established a new standard of care for BRAF V600E mutant metastatic colorectal cancer, doubling overall survival from 15 months to 30.3 months. 4.⁠ ⁠MATTERHORN: Understand the use of durvalumab in the perioperative and postoperative setting with the FLOT regimen for resectable gastric and GE junction adenocarcinoma, showing significant improvements in event-free survival. 5.⁠ ⁠DESTINY Gastric04: Delved into the findings that confirm TDXd as a preferred option in the second line and beyond for HER2 positive metastatic gastric cancer or GE junction adenocarcinoma. YouTube: https://youtu.be/hllyI5S2Dqg Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Tune in for an insightful discussion that will keep you updated on the latest advancements in GI oncology! Don't forget to subscribe for more episodes on treatment algorithms, FDA approvals, and conference highlights.

In this episode:In the MMB we spotlight the increasing dangers cyclists face on the road today, a topic that weighs heavily on the minds of many. With statistics showing a shocking rise in cyclist fatalities, Jeff and Juliet dig into the science behind these incidents and share their own experiences of fear and frustration. It's not all doom and gloom, though! They offer practical advice on how to stay safe while cycling, including the importance of visibility and the benefits of riding in groups. Through their banter, we also get a glimpse of the community aspect of cycling—the camaraderie, the shared struggles, and the collective push to make our roads safer. Because let's face it, if we can't enjoy our rides, what's the point?Then we dive into the life of Joe Lavelle that reveals a world where adventure and athleticism collide in the most delightful ways. Imagine scaling the heights of Colorado's famous 14ers, racing crits, and then swapping tales of daring escapades over a podcast microphone. That's Joe for you! In this episode, we explore his journey from a skinny kid with a desire to bulk up to a seasoned athlete who embraces the challenges of aging with grace and humor. Joe's tales are rich with the kind of wisdom that only comes from years of pushing boundaries—whether it's deciding to tackle the Matterhorn or simply choosing to get off the couch and onto a bike. We laugh, we reflect, and we nod in agreement when he emphasizes the importance of filling life with powerful memories. Because really, who doesn't want to look back and say, “Heck yeah, I did that!”?Segments:[07:40]- Medical Mailbag: Cyclist deaths on the rise[34:56]- Interview: Joe Lavelle LinksJoe's Website

A recap of notable updates from ASCO 2025 1. Destiny-Breast09 2. BREAKWATER 3. ATOMIC 4. Delphi-304 5. CM 816 OS update 6. C-POST 7. Matterhorn

In this lively and relatable episode of My Simplified Life, Michelle Glogovac and Stephanie Hockersmith share candid reflections on recent family vacations, the chaos of end-of-school-year activities, and the art of juggling parenting with personal time. From cruise ship competitions and school projects to navigating theme park rides with kids, Michelle and Stephanie dive into the real-life moments that define modern motherhood. They chat about family dynamics at Disney and Epcot, the magic of creating lasting memories, and how ride preferences can spark deeper insights into our kids' personalities. The conversation also touches on the importance of conservation, finding everyday peace amidst chaos, and why summer is the perfect time to reconnect—with your family and yourself. To wrap up, they share their most-anticipated summer book picks and how the right read can shift your mindset, inspire growth, and spark joy. Whether you're planning your own family trip or just trying to survive the summer shuffle, this episode offers laughs, heart, and a reminder that stories—both lived and read—matter deeply. What We're Talking About... Vacation can feel like another dimension. It's important to romanticize everyday life. Real life often interrupts our vacation mindset. Family trips can create lasting memories. Unexpected talents can emerge in fun situations. School projects often fall on parents' shoulders. End of school year can be hectic for families. Summer should be a time for relaxation and fun. Traveling with family requires careful planning. Finding joy in small moments is essential. Stephanie shares her fear of Ferris wheels and how she copes with it. The Matterhorn ride at Disneyland is nostalgic but physically challenging. Children have unique preferences and fears regarding rides. Conversations about respecting children's choices in activities are important. Cooper's passion for conservation shines through in his interests. Finding moments of peace in daily life is crucial for mental health. Books can provide inspiration and refresh our minds. Anticipating summer reads can be an exciting experience. Women have historically shown incredible strength and resilience. Literature can be a source of joy and connection.  Chapters 00:00 Vacation Reflections and Family Adventures 03:03 The Joys and Challenges of Family Life 05:58 Cruise Competition and Unexpected Talents 08:48 Back to Reality: School Projects and Responsibilities 12:04 Navigating the End of School Year 15:00 Summer Plans and Travel Discussions 18:42 Thrills and Chills at Theme Parks 22:34 Family Dynamics and Ride Preferences 24:59 Passion for Conservation and Nature 29:30 Finding Peace Amidst Chaos 30:47 Books That Inspire and Refresh 36:28 Anticipating Summer Reads

This week on the podcast, Worn & Wound contributor Cait Bazemore makes her podcast debut. Cait has been writing about watches for years, and in this episode we spend most of our time discussing her recent piece on Biwi, a Swiss firm which has gained some fame recently for their work with Norqain. Biwi is a fascinating company and has manufactured rubber straps and a whole host of other things for watch brands over the years, and the story of how Cait came across the story and what she discovered at Biwi's facilities in Switzerland is truly fascinating. Before the Biwi talk begins, Cait takes us through her path in the watch industry, what's interesting to her about the community, and how her interest in traditional craftsmanship relates to the high tech world of Biwi. To stay on top of all new episodes, you can subscribe to The Worn & Wound Podcast on all major platforms including Apple Podcasts, Stitcher, Spotify, and more. You can also find our RSS feed here.And if you like what you hear, then don't forget to leave us a review.If there's a question you want us to answer you can hit us up at info@wornandwound.com, and we'll put your question in the queue. Show Notes  This is the Company Quietly Making the Rubber Straps for Nearly Every Brand in the IndustryColorado's Best Kept Secret: The 5280 Watch Company is Making Timepieces with Enamel Dials for Under $4,000Jean-Claude Biver, the Matterhorn, and Carbon Fiber with Some Color: A Few Days in Zermatt with Norqain and the New Wild OneThe Press Box podcastI Do Everything I'm Told by Megan FernandesAftersun